Navigation Links
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Date:4/2/2009

and technical issues; clinical trials, including the DURATION-2 clinical trial mentioned in this press release, not being completed in a timely manner, not confirming previous results, or not achieving the intended clinical endpoints; pre-clinical trials not predicting future results; label expansion requests or New Drug Application ("NDA") filings, including the NDA filing for exenatide once weekly, not being submitted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA, SYMLIN and/or exenatide once weekly may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products. These risks also include a potential adverse impact on our financial condition if the steps outlined in this press release to address the change of control provisions in two of our debt agreements are unsuccessful and we are required to repay the amounts outstanding under any of our debt agreements. These and additional risks and uncertainties are described more fully in Amylin's most recent SEC filings including its Annual Report on Form 10-K. Amylin undertakes no duty to update these forward-looking statements.

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin will be filing a proxy statement with the Securities and Exchange Commission ("SEC"). INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and securityholders will be able to receive the proxy statement and other re
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... A newly launched business plan contest will ask startup companies from around the ... R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and medium enterprises ... mentorship from a senior industry figure drawn from the Pistoia Alliance membership. , The ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a ... address unmet medical needs in women,s health, today ... present at the Cantor Fitzgerald Inaugural Healthcare Conference ... 4:45 PM EDTLocation: , Le Parker Meridien Hotel, ... www.juniperpharma.com, under  ,Investor, or  click here ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed to ... shares (including shares of unvested restricted stock). On June 29, 2015, the last trading ... Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The tender offer ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... AMSTERDAM, December 15, 2011 Amsterdam Molecular Therapeutics ... therapy, announced today that the Company has a negative equity ... of this negative equity position is in line with previous ... is exploring alternatives for additional financing. AMT announced ...
... discovery of a new way to tune and enhance thermal ... for a given material gives engineers a new tool ... and a number of other powered devices. The finding ... Li, associate professor of mechanical engineering at Vanderbilt University, and ...
... SHANGHAI, Dec. 14, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development outsourcing ... Morgan,s 30th Annual Healthcare Conference, to be held in ... Michael Xin Hui, founder and Chief Executive Officer of ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Announces Negative Equity Position 2Amsterdam Molecular Therapeutics Announces Negative Equity Position 3New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 2New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 3
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... French . , Chicken sold in supermarkets, restaurants ... urinary tract infections (UTI), McGill researcher Amee Manges has discovered. ... in collaboration with the Public Health Agency of Canada and ... E. coli ( Escherichia coli ) bacteria originating from ...
... the first evidence from human research that blueberries ... other so-called phytochemicals improve memory. They said the ... to determine whether blueberries really deserve their growing reputation ... appears in ACS, Journal of Agricultural and Food ...
... a jury could decide a man,s guilt through mind reading? ... And what constitutes ,intent, to commit murder? These are ... inaugural issue of WIREs Cognitive Science, the latest interdisciplinary project ... the first two years. In the article "Neurolaw," ...
Cached Biology News:Retail meat linked to urinary tract infections: Strong new evidence 2Mind reading, brain fingerprinting and the law 2
... The nature of proteomics demands the ... The superior performance of the AXIMA-CFRplus with ... than 5 ppm) provides increased confidence in ... blanking for enhanced sensitivity, automated sample target ...
... Axima range, the AXIMA-CFR provides a ... sensitivity and mass range, and offers ... reflectron time-of-flight analysis. The unique patented ... of seamless PSD, providing efficient and ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
...
Biology Products: